FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2159480705> ?p ?o ?g. }

• W2159480705 endingPage "95" @default.
• W2159480705 startingPage "55" @default.
• W2159480705 abstract "On 20 February 2007, Prime Minister Stephen Harper announced a commitment by the Government of Canada and the Bill & Melinda Gates Foundation to fund and support the Canadian HIV Vaccine Initiative (CHVI), (1) an effort to accelerate the development of an HIV/AIDS vaccine and address critical research gaps identified by the Global HIV/AIDS Vaccine Enterprise (GHAVE). (2) The goal of the CHVI is to coordinate research within Canada as well as Canadian contributions to the international efforts to develop safe, effective, affordable, and globally accessible vaccines. (3) Canada's commitment to HIV vaccine research is longstanding. In 2002, Canada promised at the XIV International AIDS Conference, held in Barcelona, to develop a Canadian HIV/AIDS vaccine plan focusing vaccine production and equitable distribution ... this plan will support the global vaccine effort and will contribute to a better understanding of the complex legal, ethical and human rights issues involved in addressing access to vaccines and treatments for people living with HIV/AIDS, nationally and globally. (4) The Canadian HIV Vaccines Plan: Towards a World Without AIDS was published in 2006, (5) and calls for Canada to contribute towards global efforts to develop and deliver HIV vaccines, including strong community-based organizations; a strong research capacity; immune-monitoring capability; long-term relationships with research partners in the developing world; infrastructure in Canada and internationally; recognition of our strengths in social science, legal issues and human rights; new possibilities for production plants; emerging private-public sector partnerships; international recognition for diplomacy; and a strong health care ... system. (6) To accomplish these goals, it is necessary to ascertain and respond to the key non-science challenges to HIV vaccine research in Canada, focusing on any potential intellectual property (IP) bottlenecks. This paper builds upon the key issues identified in Part One of this series of two papers on Challenges for Intellectual Property Management of HIV Vaccine-Related Research and Development [hereinafter, Part One]. Following that review of the global literature and consultations with international experts, (7) we consulted with representatives from the CHVI and developed sector-specific interview guides for academic researchers, government, and industry representatives in Canada. We conducted individual or group interviews with 21 key informants in Canada, including CHVI representatives, experts in intellectual property law, management and ethics, as well as academic and private sector HW vaccine researchers. (8) Here, we present the conclusions from those interviews, a discussion of key concerns, and potential solutions. The consultations focused on the main non-science barriers to HIV vaccines (R&D) in Canada. The main challenges identified from a research perspective surprisingly did not include issues related to IP, but were, instead, inadequate funding for research, clinical trials and gap funding for taking innovative research to the proof of principle stage. There are also problems associated with the creation of effective research networks and collaborative models. Further downstream, there will be major challenges associated with manufacturing and distributing vaccines, particularly in developing countries, and the associated risks of liability for adverse events, such as allergic reactions to the vaccine. This latter issue has already come to the fore in HIV vaccine clinical trials known as the Step Study. The vaccine, manufactured by Merck and Co., was found to increase the susceptibility of participants to HW infection if they had high levels of antibodies to adenovirus 5. Adenovirus 5 was a component of the vaccine and is one of the causes of the common cold. Indeed, an independent Data and Safety Monitoring Board went so far as to recommend unblinding the results and notifying participants whether they received the Merck vaccine or the placebo. …" @default.
• W2159480705 created "2016-06-24" @default.
• W2159480705 creator A5063405711 @default.
• W2159480705 creator A5089546614 @default.
• W2159480705 date "2008-01-01" @default.
• W2159480705 modified "2023-09-26" @default.
• W2159480705 title "Challenges for intellectual property management of HIV vaccine-related research and development: part 1, the global context." @default.
• W2159480705 doi "https://doi.org/10.7939/r39g5gf7c" @default.
• W2159480705 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19536979" @default.
• W2159480705 hasPublicationYear "2008" @default.
• W2159480705 type Work @default.
• W2159480705 sameAs 2159480705 @default.
• W2159480705 citedByCount "1" @default.
• W2159480705 countsByYear W21594807052018 @default.
• W2159480705 crossrefType "journal-article" @default.
• W2159480705 hasAuthorship W2159480705A5063405711 @default.
• W2159480705 hasAuthorship W2159480705A5089546614 @default.
• W2159480705 hasConcept C138816342 @default.
• W2159480705 hasConcept C138885662 @default.
• W2159480705 hasConcept C151730666 @default.
• W2159480705 hasConcept C159110408 @default.
• W2159480705 hasConcept C160735492 @default.
• W2159480705 hasConcept C162324750 @default.
• W2159480705 hasConcept C17744445 @default.
• W2159480705 hasConcept C203014093 @default.
• W2159480705 hasConcept C2778137410 @default.
• W2159480705 hasConcept C2778190748 @default.
• W2159480705 hasConcept C2779343474 @default.
• W2159480705 hasConcept C2780195530 @default.
• W2159480705 hasConcept C3013748606 @default.
• W2159480705 hasConcept C3116431 @default.
• W2159480705 hasConcept C39549134 @default.
• W2159480705 hasConcept C41895202 @default.
• W2159480705 hasConcept C46578552 @default.
• W2159480705 hasConcept C50522688 @default.
• W2159480705 hasConcept C71924100 @default.
• W2159480705 hasConcept C86803240 @default.
• W2159480705 hasConceptScore W2159480705C138816342 @default.
• W2159480705 hasConceptScore W2159480705C138885662 @default.
• W2159480705 hasConceptScore W2159480705C151730666 @default.
• W2159480705 hasConceptScore W2159480705C159110408 @default.
• W2159480705 hasConceptScore W2159480705C160735492 @default.
• W2159480705 hasConceptScore W2159480705C162324750 @default.
• W2159480705 hasConceptScore W2159480705C17744445 @default.
• W2159480705 hasConceptScore W2159480705C203014093 @default.
• W2159480705 hasConceptScore W2159480705C2778137410 @default.
• W2159480705 hasConceptScore W2159480705C2778190748 @default.
• W2159480705 hasConceptScore W2159480705C2779343474 @default.
• W2159480705 hasConceptScore W2159480705C2780195530 @default.
• W2159480705 hasConceptScore W2159480705C3013748606 @default.
• W2159480705 hasConceptScore W2159480705C3116431 @default.
• W2159480705 hasConceptScore W2159480705C39549134 @default.
• W2159480705 hasConceptScore W2159480705C41895202 @default.
• W2159480705 hasConceptScore W2159480705C46578552 @default.
• W2159480705 hasConceptScore W2159480705C50522688 @default.
• W2159480705 hasConceptScore W2159480705C71924100 @default.
• W2159480705 hasConceptScore W2159480705C86803240 @default.
• W2159480705 hasLocation W21594807051 @default.
• W2159480705 hasLocation W21594807052 @default.
• W2159480705 hasOpenAccess W2159480705 @default.
• W2159480705 hasPrimaryLocation W21594807051 @default.
• W2159480705 hasRelatedWork W1849202995 @default.
• W2159480705 hasRelatedWork W1974786639 @default.
• W2159480705 hasRelatedWork W2029980469 @default.
• W2159480705 hasRelatedWork W2032706985 @default.
• W2159480705 hasRelatedWork W2033572243 @default.
• W2159480705 hasRelatedWork W2033929009 @default.
• W2159480705 hasRelatedWork W2049051676 @default.
• W2159480705 hasRelatedWork W2053754724 @default.
• W2159480705 hasRelatedWork W2084288833 @default.
• W2159480705 hasRelatedWork W2105775550 @default.
• W2159480705 hasRelatedWork W2156438956 @default.
• W2159480705 hasRelatedWork W2206959031 @default.
• W2159480705 hasRelatedWork W2303713298 @default.
• W2159480705 hasRelatedWork W2410396357 @default.
• W2159480705 hasRelatedWork W2464440794 @default.
• W2159480705 hasRelatedWork W2969378788 @default.
• W2159480705 hasRelatedWork W3124530915 @default.
• W2159480705 hasRelatedWork W2183893715 @default.
• W2159480705 hasRelatedWork W2284561311 @default.
• W2159480705 hasRelatedWork W2618325718 @default.
• W2159480705 hasVolume "16" @default.
• W2159480705 isParatext "false" @default.
• W2159480705 isRetracted "false" @default.
• W2159480705 magId "2159480705" @default.
• W2159480705 workType "article" @default.